Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline UK and US Performance Share Plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions. The only financial data points disclosed are the share prices used for notional re-investment on January 8, 2013:
- Ordinary Share Price: 1363.50 pence
- American Depositary Share (ADS) Price: $43.98
Material Changes
The filing details increases in notional interests in Ordinary Shares and ADSs for various executives following the notional re-investment of the dividend paid to shareholders on January 3, 2013. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Key Facts for Investor Verification
- Dividend re-investment occurred on January 8, 2013, following a dividend payment on January 3, 2013.
- Transactions were executed at 1363.50 pence per Ordinary Share and $43.98 per ADS.
- Notional share increases were recorded for 15 named executives, including Sir Andrew Witty (20,450.937 Ordinary Shares) and Dr M M Slaoui (6,122.035 ADSs).
- Payouts are contingent upon the vesting of Performance Share Plan holdings after a three-year measurement period.